Titan Medical Inc. ("the Company") (TSX VENTURE: TMD)(OTCQX: TITXF)

announced that today the Company's common shares commenced trading on

the international tier of the OTCQX market in the United States under

the ticker symbol "TITXF".

Investors can find current financial disclosure and Real-Time Level 2

quotes for the Company on and

"We are pleased to be listed on the OTCQX market, which will provide

our current and potential investors in the U.S. with a better platform

to access our company's securities," said Craig Leon, Chief Executive

Officer of Titan Medical, Inc. "As we continue to execute our growth

strategy, the OTCQX listing will help us increase Titan's awareness

among the investment community in the U.S."

Dorsey & Whitney LLP will serve as the Company's Principal American

Liaison on OTCQX, responsible for providing guidance on OTCQX

requirements and U.S. securities laws.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates the world's largest

electronic marketplace for broker-dealers to trade unlisted stocks.

Its OTC Link platform supports an open network of competing

broker-dealers that provide investors with the best prices in over

10,000 OTC securities. It categorizes the wide spectrum of OTC-traded

companies into three tiers - OTCQX (the intelligent marketplace),

OTCQB@ (the venture marketplace), and OTC Pink (the open marketplace)

- so investors can identify the level and quality of information

companies provide. To learn more about how OTC Markets Group makes the

unlisted markets more transparent, informed, and efficient, visit

About Titan Medical Inc.

Titan Medical Inc. is a Canadian public company (TSX VENTURE:

TMD)(OTCQX: TITXF) focused on the development and commercialization of

robotic surgical technologies. The Company is currently developing

Amadeus Composer, a surgical system that has a uniquely designed

external robot and flexible instruments, with the objective of

allowing surgeons to overcome constraints of surgical procedures in

small to medium spaces. Amadeus Maestro, the Company's next

generation 4-armed robotic surgical system with advanced communication

and training, utilizes the Titan True Touch Technology and is targeted

to surgical procedures in large spaces. Robotic surgery has developed

over the past 10 years into a proven and growing method of treatment.

The global robotic surgical market size is currently estimated to be

approximately $1 billion and is estimated to grow to $5 billion by

2015 with potential for placement of 6,000 robotic surgical systems.

The Company is researching and developing innovative technologies to

empower surgeons to use robots in the operating room of the future.

For more information, visit the Company's website at

Forward Looking Statements

This news release contains "forward-looking statements" which reflect

the current expectations of management of the Company's future growth,

results of operations, performance and business prospects and

opportunities. Wherever possible, words such as "may", "would",

"could", "will", "anticipate", "believe", "plan", "expect", "intend",

"estimate", "potential for" and similar expressions have been used to

identify these forward-looking statements. These statements reflect

management's current beliefs with respect to future events and are

based on information currently available to management.

Forward-looking statements involve significant risks, uncertainties

and assumptions. Many factors could cause the Company's actual

results, performance or achievements to be materially different from

any future results, performance or achievements that may be expressed

or implied by such forward-looking statements, including, without

limitation, those listed in the "Risk Factors" section of the

Company's Annual Information Form dated March 31, 2011 (which may be

viewed at Should one or more of

these risks or uncertainties materialize, or should assumptions

underlying the forward looking statements prove incorrect, actual

results, performance or achievements may vary materially from those

expressed or implied by the forward-looking statements contained in

this news release. These factors should be considered carefully and

prospective investors should not place undue reliance on the

forward-looking statements. Although the forward-looking statements

contained in the news release are based upon what management currently

believes to be reasonable assumptions, the Company cannot assure

prospective investors that actual results, performance or achievements

will be consistent with these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as

that term is defined in policies of the TSX Venture Exchange) accepts

responsibility for the adequacy or accuracy of this release.